Kornimate/medical-research-clean huggingface dataset:
establishment and validation of a clinical predictive model for gastrointestinal cancer screening based on patient-related risk factors

Conditions: Malignant Tumor of Digestive Tract; Risk Factors

Summary: gastrointestinal tumors (esophageal cancer, gastric cancer, colorectal cancer) seriously threaten human health, with a high incidence rate and cancer related hope mortality. digestive endoscopy is the main method for screening gastrointestinal tumors. early screening of gastrointestinal tumors can improve the detection of early cancer and improve prognosis. the five-year survival rate of early stage tumors after comprehensive treatment can reach 90%, while the five-year survival rate of late stage tumors is less than 30%. therefore, the screening of gastrointestinal tumors is very important. studies have shown that there are similarities in risk factors for gastrointestinal tumors, such as age, gender, family history, smoking, alcohol consumption, etc. currently, established digestive malignancies are targeted at a single malignant tumor. at present, there is a lack of understanding of the overall risk factors associated with gastrointestinal tumors and the establishment of relevant risk prediction models. therefore, we conducted a prospective, multicenter cross-sectional study to explore the independent risk factors of combined gastrointestinal tumors and establish a risk prediction model for combined screening of gastrointestinal tumors.


Eligibility criteria:
inclusion criteria: * individuals aged 18-80 who undergo both gastroscopy and colonoscopy simultaneously exclusion criteria: * （1）previously diagnosed with esophageal, gastric, or colorectal cancer; (2) suspected presence of gastrointestinal obstruction or perforation; (3) previous history of esophageal, gastric, or colorectal surgery; (4) those who are not suitable for endoscopic examination due to serious diseases or unstable hemodynamics; (5) individuals who are unable to obtain relevant information due to communication barriers such as mental or neurological disorders; (6) pregnancy or lactation period; (7) not willing or unable to sign the informed consent form.
relative adrenal insufficiency in preterm very low birth weight infants with shock

Conditions: Adrenal Insufficiency

Summary: the objective of this study is to estimate the prevalence of relative adrenal insufficiency in preterm very low birth weight infants with and without shock.

till date, no studies are available that have evaluated the incidence of relative adrenal insufficiency in preterm very low birth weight (vlbw) infants with shock. the focus had been on stable preterm and critically ill preterm infants. given that steroid treatment improves blood pressure and stabilizes cardiovascular status in preterm infants with volume and pressor-resistant hypotension,it becomes essential to examine the incidence of adrenal insufficiency in this cohort (rather than a broad group of critically ill preterm infants). moreover, there are no studies on adrenal function in indian neonates. the purpose of this study is to compare the levels of basal and stimulated (using low dose \[1µg/k\] acth) cortisol levels in preterm (28-34 weeks gestation) very low birth weight (birth weight 750 gm to 1500 gm) infants with shock in the first week of life requiring vasopressor therapy and matched (gestation, birth weight, postnatal age-matched) hemodynamically stable infants ('control group').

Eligibility criteria:
inclusion criteria: * all preterm (28 to 34 week gestation) very low birth weight (birth weight 750-1500grams.) infants born at aiims would be eligible for enrollment in the study. of these infants, those who meet the following criteria would be enrolled. * cases: preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams with shock in the first week of life requiring vasopressor therapy (dopamine or dobutamine or both in a dose of \> 10 mcg/kg/min) * controls: stable preterm (28 to 34 week gestation) infants with birth weight between 750 and 1500 grams who are matched for gestational age, birth weight, postnatal-age. exclusion criteria: * major congenital malformations * mother receiving anticonvulsant / anti-tubercular drugs (rifampicin, isoniazid) * postnatal corticosteroid treatment * refusal to give consent

Keywords: adrenal insufficiency cortisol preterm shock neonate
influence of placebo on intratissue percutaneous electrolysis in patellar tendinopathy

Conditions: Patellar Tendinopathy

Summary: the main aim of this study is to verify the influence of placebo on the effectiveness of intratissue percutaneous electrolysis (ipe) in patients suffering from with chronic patellar tendinopathy (pt). the secondary aim is to investigate the possible influence of the ipe on pain perception and conditioned pain modulation (cpm) in patients with chronic pt.

the aim of this study is to investigate the influence of placebo on the effectiveness of intratissue percutaneous electrolysis (ipe) in patients with chronic pt. for this purpose a randomized clinical trial will be carried out, with a sample of patients diagnosed of chronic pt based on signs, symptoms and clinical examination. subjects will be randomly allocated to four different groups: group e1, ipe will be applied, participants will believe they are receiving ipe; group e2, ipe will be applied, participants will believe they are receiving placebo; group p1, ipe will not be applied, participants will believe they are receiving ipe; and group p2, ipe will not be applied, participants will believe they are receiving placebo. ipe treatment will consist of a total of 3 sessions, with a time interval of one week between the 1st and 2nd sessions and 2 weeks between the 2nd and 3rd sessions. to evaluate the effect of intervention, the subjects will be assessed at baseline (v0), one week after the end of the intervention (v1) and 3 weeks after the intervention (v2). in v0, sociodemographic (sex, age, profession, height, body mass index (bmi), sport activity, hours of sport per week) and clinical data (associated pathologies, affected lower limb, dominant lower limb, duration of symptoms) will be registered. in each assessment time information regarding bmi, sports activity, hours of sport per week and location of pain will be obtained. moreover, in all assessments participants were evaluated for four physical performance tests, pain and functional scales, ultrasound examination, pressure pain thresholds, conditioned pain modulation, and expectations questionnaires.

Eligibility criteria:
inclusion criteria: * 18 years old or older * presenting the following signs and symptoms of patellar tendinopathy: pain when jumping, landing, running o changing direction, pain at the inferior pole of the patella, victorian institute of sport assessment-patella (visa-p) score \<80, symptoms duration of at least 3 months. exclusion criteria: * prior knee surgery * patients having received local corticosteroids injection in the tendon within the preceding 6 months * patients presenting any inflammatory disease, metabolic bone disease, type ii diabetes, fibromyalgia, hypercholesterolemia, pregnancy or chemotherapy within the 3 months prior to the study.
anti-infection of low-does il-2 in sle

Conditions: Systemic Lupus Erythematosus

Summary: the objective of this clinical study is to evaluate the potential effect of anti-infection of low-does il-2 in patients with sle.

systemic lupus erythematosus (sle) is a chronic autoimmune syndrome affecting various organs.many feel that glucocorticoid and immunosuppressor are the standard therapy for patients with sle. while it can improve the risk of infection among sle patients. a novel therapy to treat sle with low-does il-2 has been identified recently. il-2 also used to against some virus infect. so we hypothesized that low-dose il-2 could reduce risk of infection in sle patients. methods: a total of sle patients (n=30) were divided into two groups randomly. one received standard therapy, while another one administrate with low-does il-2 plus standard therapy.each patient will be treated with low-dose il-2. the end points are clinical and immunologic response. expected results: this trail wlii provide both clinical and basic profe that low-dose il-2 plus standard therapy have lower infection risk in sle patients.

Eligibility criteria:
inclusion criteria: * meet the american college of rheumatology criteria for the diagnosis of sle. * under standard treatment (≥ 2 months) at the time of inclusion * background treatment failed to control flares or to permit prednisone tapering * with at least one of the following manifestations: thrombocytopenia, disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis, renal disorder(proteinuria\>0.5g/day), neuropsychiatric sle. * positive for at least one of the following laboratory tests: ana\>1:160, anti-dsdna, immunoglobulin\>20g/l, decreased c3 or c4, leukopenia\<3×10\^9/l, thrombocytopenia\<100×10\^9/l; * sle disease activity index(sledai) ≥ 8. * negative hiv test. * negative for hepatitis b and c virus. * written informed consent form. exclusion criteria: * sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade iii nyha), hepatic insufficiency (transaminases\> 3n) ) * serious infection such as bacteremia, sepsis; * cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma); * high-dose steroid pulse therapy (\>1.5mg/kg) or iv bolus of corticosteroids in the last 2 months. * history of administration of rituximab or other biologics; * purified protein derivative (tuberculin) \>10mm * mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information; * inability to comply with il-2 treatment regimen.

Keywords: sle,il-2
a study to determine effective prophylaxis and treatment of nelfinavir-associated diarrhea

Conditions: Diarrhea

Summary: the purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.


Eligibility criteria:
inclusion criteria: * antiretroviral-naive patients with hiv-1 infection * not more than 2 loose stools per day or any preexisting or emerging medical condition that would interfere with the evaluation of therapeutic response of the study drug * no antidiarrheal medication within 7 days prior to entry exclusion criteria: * greater than or equal to 2 loose stools per day lasting 2 or more days within 7 days prior to study entry * bloody stools within 7 days prior to study entry * any unstable or severe intercurrent medical condition, including active opportunistic infections
naftopidil 75mg for improving clearance of urinary stones

Conditions: Kidney Calculi; Ureter Calculi

Summary: the purpose of this study is to evaluate efficacy and safety of oral intake of naftopidil 75mg once daily for the improving clearance of ureteral or renal stones.

prospective, single-center, double blind, randomized controlled trial treatment - oral naftopidil 75 mg once daily are given to the patients who are scheduled for shockwave lithotripsy (eswl) because of ureteral or renal stones. follow up assessments including x-ray(kub), visual analogue pain scale, are done 2, 4, and 6 weeks after the eswl.

Eligibility criteria:
inclusion criteria: * radio-opaque (identifiable in kub) ureter or kidney calculi * size criteria is from 5mm to 15mm exclusion criteria: * symptomatic acute urinary tract infection during the run-in period * severe hydronephrosis * 2 or more urinary stones * radiolucent (non-visible in kub) stone * recent intervention for the urinary stone within 6 month * patients who have ureteral stent * over 2.0 mg/dl of serum creatinine level * severe hepatic dysfunction * orthostatic hypotension * current usage of alpha-adrenergic blocker or calcium channel blocker * pregnant or nursing women * age under 15 year * severe or uncontrolled medical conditions

Keywords: medical expulsive therapy
semmelweis sport study

Conditions: Athletes Heart

Summary: the aim of the present proposal is to investigate the development of distinct morphological, functional, biochemical and molecular aspects of short- and long-term sport-induced changes in the heart, to get a better understanding on the (patho)physiology of athlete's heart. the main goal of our research is to deepen our knowledge on the proper differentiation between beneficial (physiological) and harmful (pathological) consequences of professional sport, thereby effectively preventing potential cardiovascular complications of athletes.

clinical methods 1. sport specific questionnaire, patient history and physical examinations - in our detailed questionnaire, specific information is collected about quantity and quality of training, personal and family history and presence of sport specific and general symptoms. 2. laboratory biochemical examination - besides the regular routine laboratory parameters, several specific parameters associated with physical exercise are planned to be measured, such as cardiac biomarkers. 3. 12-lead ecg - resting standard 12-lead digital ecg will be recorded. extended analysis will be performed according to the latest recommendations. 4. holter ecg - 24 hour holter ecg will be recorded. extended holter ecg analysis will be performed. 5. detailed echocardiography 6. detailed cmr examination 7. body composition analysis - with a sophisticated bio-electrical impedance analysis, comprehensive whole body composition and hydration analysis will be performed. 8. cardiopulmonary exercise testing - sport specific protocols will be used on both treadmill and bike ergometers.

Eligibility criteria:
inclusion criteria: * age * no known cardiovascular disease * history of sport activity (athletes) * no history of competitive sport (controls) exclusion criteria: * history of known relevant cardiac disease (including cardiomyopathies) * contraindication to mri or cardiopulmonary exercise testing

Keywords: hypertrophy, left ventricular ventricular remodeling
an observational study to evaluate lymph metastases and prognoses of the patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: the real-world observational study was designed to explore lymph metastases and prognoses of the chinese patients with thoracic t1-t3 esophageal cancer

this trial is a real-world non-interventional observational study. the chinese patients with thoracic t1-t3 esophageal cancer enrolled from jan.1999 to jun.2017 were included and the study data on pathologically diagnosed patient demographic/tumor biological characteristics were collected to evaluate the relevance of lymph metastases and prognoses of the subjects.

Eligibility criteria:
inclusion criteria: * patients \>= 18 years old; * patients who received radical resection of esophageal cancer; * pathologically diagnosed patients with thoracic t1-t3 esophageal cancer after surgeries; exclusion criteria: * patients who received upper gastrointestinal surgeries; * patients with second primary tumors;

Keywords: chinese, real-world evidences, t1-t3 esophageal cancer
compression treatment of superficial vein thrombosis

Conditions: Pain; Erythema; Thrombus Length; Quality of Life

Summary: leg compression is considered the basic treatment for superficial vein thrombosis (svt). however, its use is more or less based on subjective experience while scientific evidence for its efficacy is lacking. there is one uncontrolled trial reporting improvement of clinical symptoms when patients with svt were treated with fixed compression bandages. this study evaluates the efficacy of compression stockings (23-32 mmhg) in the treatment svt of the legs. the investigators hypothesis is that compression treatment is superior to no compression in alleviating disease related clinical symptoms.


Eligibility criteria:
inclusion criteria: * patients with superficial vein thrombosis of the leg, * thrombus extent of at least 5 cm confirmed by duplex sonography, * clinical signs of inflammation (pain, erythema) exclusion criteria: * superficial thrombus distance to the saphenofemoral or saphenopopliteal junction of less than 2cm, * concomitant deep vein thrombosis, * thrombophilia, * active malignoma, * immobility, * peripheral arterial occlusive disease, * superficial vein thrombosis after sclerotherapy * incision and clot expression * excessive leg configuration not covered by ready made compression stockings
comparison of the medication adherence of patients treated with telmisartan/hydrochlorothiazide or telmisartan/amlodipine fixed dose combination (fdc) versus double-pill combination therapy in real-world japanese therapeutic practice

Conditions: Hypertension

Summary: the primary objective of this study is to compare the medication adherence measured by pdc of patients with fdc or double-pill combination therapy in real-world japanese therapeutic practice.the further objective of this study is how much influence the background of patients to the adherence.


Eligibility criteria:
inclusion criteria: * patients with hypertension * patients must have their first prescription (defined as index date\*) for telmisartan and hydrochlorothiazide or micombi® between 01/07/2010 and 28/09/2010 * patients must have their first prescription (defined as index date\*) for telmisartan and amlodipine or micamlo® between 10/12/2010 and 09/03/2011 * patients must have at least 180 days follow up verified by the presence of prescription record exclusion criteria: * patients who were under 40 years old at the time of enrolment * patients who prescribed the study drugs less than 90 days during a follow up period of 180 days * patients whose visits are less than 2 times during a follow up period of 180 days
vitabreath pilot in chronic obstructive pulmonary disease (copd) patients

Conditions: COPD; Dyspnea

Summary: dyspnea is the most common symptom limiting the ability of copd patients to perform activities of daily living. although there has been research involving the benefit of providing non invasive ventilation (niv) during exercise to increase tolerance overall, there is little research specifically looking at shortening dyspnea recovery times associated with exercise. we hypothesize that providing intermittent non-invasive positive pressure therapy (a form of niv or pap) with a handheld device to copd patients immediately after exertion can relieve their dyspnea, and consequently allow them to be more active. in this study, we are comparing the distance walked as measured by a modified 6-minute walk test (6mwt) of 20 copd patients using vitabreath (niv) device versus pursed lip breathing.


Eligibility criteria:
inclusion criteria: * age ≥ 40 * ability to provide consent * copd diagnosis * forced expiratory volume in one second (fev1) \<55 and ≥ 25 percent of predicted value * perceived shortness of breath via the modified medical research counsel dyspnea questionnaire (rating of 2 or greater) (appendix b) * able to follow directions * able to tolerate mild physical activity * pursed lip breathing as standard of care * no evidence of bullous lung disease (with any bullae greater than 3cm in diameter) as confirmed by a ct scan within the past one year. exclusion criteria: * subjects who are acutely ill, medically complicated or who are medically unstable as determined by the investigator. * suffering from copd exacerbation at time of enrollment or 60 days prior * subjects who are not currently prescribed oxygen and manifest oxygen desaturation below 88% on the screening 6mwt * subjects with heart disease or neuromuscular disease. * subjects who are not prescribed short-acting bronchodilator medication * patients who have experienced recent barotrauma or pneumothorax * unstable angina or myocardial infarction during past month * uncontrolled hypertension (systolic blood pressure of \>180mmhg (millimeters of mercury) and a diastolic \>100mmhg) * heart rate \>120 at rest * subjects who have trouble coordinating their breathing with the device during the device training, or cannot tolerate the device mouthpiece resulting in leaks from the nasal cavity * women of child-bearing potential (wocp) who are pregnant, breast-feeding, or planning pregnancy during the course of the study. (wocp must have a negative pregnancy test at every visit)
post-transition clinical and socio-professional future in adult patients with recurrent multifocal chronic osteitis

Conditions: Chronic Recurrent Multifocal Osteomyelitis

Summary: chronic recurrent multifocal osteomyelitis (crmo) is a rare autoinflammatory bone disease in children. studies evaluating the quality of life of patients with crmo are small and heterogeneous. a better understanding of the impact of the disease on the quality of life of adult patients with crmo beginning in childhood would allow better long-term management of these patients. our study aims are to assess the clinical and socio-professional outcomes of adult patients who started crmo at pediatric age.


Eligibility criteria:
inclusion criteria: * adult patient with a crmo with pediatric-onset disease (\> 18years) * patient who was informed and agreed to participate in this study exclusion criteria: * patients with monogenic auto-inflammatory disease associated with osteolytic bone lesions (e.g. interleukin-1 receptor antagonist deficiency) * patient with majeed syndrome * patient without sufficient imaging data to confirm the presence of one or more inflammatory lesions * patients with incomplete data. * patients placed under legal protection, guardianship or curatorship
early therapy of pulmonary arterial hypertension

Conditions: Pulmonary Hypertension; Systemic Sclerosis

Summary: exercise-induced increase of the pulmonary arterial pressure may be an early sign of pulmonary arterial hypertension. it has been shown that patients with normal pulmonary arterial pressure at rest but elevated pulmonary arterial pressure during exercise have a decreased exercise-capacity and may have a worse prognosis compared to patients with normal pulmonary arterial pressure values at rest and during exercise. according to the currently used definition pulmonary hypertension can be diagnosed if the mean pulmonary arterial pressure is higher than 25mmhg at rest or 30mmhg during exercise. in this study patients with a risk for pulmonary arterial hypertension (connective tissue disease) and increased pulmonary arterial pressure values during exercise are receiving a therapy with a dual endothelin receptor antagonist - bosentan, a therapy established for pulmonary arterial hypertension. the therapy effect is than compared to the recorded changes before the introduction of this therapy.

bosentan is an established therapy in pulmonary arterial hypertension, which may be diagnosed when the mean pulmonary arterial pressure is \>25mmhg at rest or \>30mmhg at exercise. bosentan has shown efficacy, if mean pulmonary arterial pressure was elevated at rest. however, there are no data available of the effects of such a therapy, if the mean pulmonary arterial pressure is normal at rest but elevated during exercise. the purpose of this study is to provide additional data on this group of patients. our hypothesis is that patients with exercise-induced pulmonary hypertension may show a gradual worsening of pulmonary hemodynamics and potentially a development of manifest pulmonary arterial hypertension (elevated resting pulmonary arterial pressure values) without treatment, while the introduction of bosentan may improve hemodynamics and exercise capacity in this patient group.

Eligibility criteria:
inclusion criteria: * exercise-induced pulmonary hypertension * systemic sclerosis exclusion criteria: * relevant pulmonary obstruction or restriction * relevant left cardiac disease * recent changes in medical therapy * recent major operations * recent major cardiovascular diseases * inability to perform exercise